DONATE

Acknowledged and Supported Publications

  1. Stein L, Murugesan K, Reeser JW, et al. FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer. NPJ Precis Oncol. 2024;8(1):207. doi:10.1038/s41698-024-00683-x
  2. Lawrence YR, Miszczyk M, Dawson LA, et al. Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024;25(8):1070-1079. doi:10.1016/S1470-2045(24)00223-7
  3. Jones LW, Moskowitz CS, Lee CP, et al. Neoadjuvant exercise therapy in prostate cancer: a phase 1, decentralized nonrandomized controlledtrial. JAMA Oncol. 2024;10(9):1187-1194. doi:10.1001/jamaoncol.2024.2156
  4. Azim HA Jr, Niman SM, Partridge AH, et al. Fertility preservation and assisted reproduction in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy. J Clin Oncol. 2024;42(23):2822-2832. doi:10.1200/JCO.23.02292
  5. Khandelwal P, Langenberg L, Luebbering N, et al. A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults. Blood. 2024;143(12):1181-1192. doi:10.1182/blood.2023022865
  6. Choi BD, Gerstner ER, Frigault MJ, et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N Engl J Med. 2024;390(14):1290-1298. doi:10.1056/NEJMoa2314390
  7. Brown CE, Hibbard JC, Alizadeh D, et al. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med. 2024;30(4):1001-1012. doi:10.1038/s41591-024-02875-1
  8. Petronek MS, Bodeker KL, Lee CY, et al. Iron-based biomarkers for personalizing pharmacological ascorbate therapy in glioblastoma: insights from a phase 2 clinical trial. J Neurooncol. 2024;166(3):493-501. doi:10.1007/s11060-024-04571-z
  9. Verma A, Chi YY, Malvar J, et al. Nivolumab plus 5-azacitidine in pediatric relapsed/refractory acute myeloid leukemia (AML): phase I/II trial results from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Cancers (Basel). 2024;16(3):496. doi:10.3390/cancers16030496
  10. Petronek MS, Monga V, Bodeker KL, et al. Magnetic resonance imaging of iron metabolism with T2* mapping predicts an enhanced clinical response to pharmacologic ascorbate in patients with GBM. Clin Cancer Res. 2024;30(2):283-293. doi:10.1158/1078-0432.CCR-22-3952
  11. Petronek MS, Teferi N, Lee CY, Magnotta VA, Allen BG. MRI detection and therapeutic enhancement of ferumoxytol internalization in glioblastoma cells. Nanomaterials (Basel). 2024;14(2):189. doi:10.3390/nano14020189
  12. Zaher A, Mapuskar KA, Sarkaria JN, Spitz DR, Petronek MS, Allen BG. Differential H2O2 metabolism among glioblastoma subtypes confers variable responses to pharmacological ascorbate therapy combined with chemoradiation. Int J Mol Sci. 2023;24(24):17158. doi:10.3390/ijms242417158
  13. Zhao JL, Antonarakis ES, Cheng HH, et al. Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). Br J Cancer. 2024;130(1):53-62. doi:10.1038/s41416-023-02487-5
  14. Pabst T, Norbert V, Adès L, et al. Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. Haematologica. 2023;108(7):1793-1802. doi:10.3324/haematol.2022.281563
  15. Partridge AH, Niman SM, Ruggeri M, et al; International Breast Cancer Study Group; POSITIVE Trial Collaborators. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023;388(18):1645-1656. doi:10.1056/NEJMoa2212856
  16. Callaghan CM, Abukhiran IM, Masaadeh A, et al. Manipulation of redox metabolism using pharmacologic ascorbate opens a therapeutic window for radio-sensitization by ATM inhibitors in colorectal cancer. Int J Radiat Oncol Biol Phys. 2023;115(4):933-944. doi:10.1016/j.ijrobp.2022.10.012
  17. Petronek MS, Teferi N, Caster JM, et al. Magnetite nanoparticles as a kinetically favorable source of iron to enhance GBM response to chemoradiosensitization with pharmacological ascorbate. Redox Biol. 2023;62:102651. doi:10.1016/j.redox.2023.102651
  18. Mamot C, Wicki A, Hasler-Strub U, et al. A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer. Sci Rep. 2023;13(1):3705. doi:10.1038/s41598-023-30950-z
  19. Vaishampayan UN, Thakur A, Chen W, et al. Phase II trial of pembrolizumab and anti-CD3 x anti-HER2 bispecific antibody-armed activated T cells in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2023;29(1):122-133. doi:10.1158/1078-0432.CCR-22-1601
  20. Gunther JR, Chadha AS, Guha S, et al. A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer. J Gastrointest Oncol. 2022;13(6):2938-2950. doi:10.21037/jgo-22-259
  21. Heumann TR, Baretti M, Sugar EA, et al. A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Clin Epigenetics. 2022;14(1):166. doi:10.1186/s13148-022-01367-8
  22. Silk AW, O’Day SJ, Kaufman HL, et al. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study. Cancer Immunol Immunother. 2023;72(6):1405-1415. doi:10.1007/s00262-022-03314-1
  23. Zaher A, Stephens LM, Miller AM, et al. Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapy. Front Immunol. 2022;13:989000. doi:10.3389/fimmu.2022.989000
  24. Rajurkar M, Parikh AR, Solovyov A, et al. Reverse transcriptase inhibition disrupts repeat element life cycle in colorectal cancer. Cancer Discov. 2022;12(6):1462-1481. doi:10.1158/2159-8290.CD-21-1117
  25. Petronek MS, Tomanek-Chalkley AM, Monga V, et al. Detection of ferritin expression in soft tissue sarcomas with MRI: potential implications for iron metabolic therapy. Iowa Orthop J. 2022;42(1):255-262. https://pubmed.ncbi.nlm.nih.gov/35821920/
  26. Msaouel P, Goswami S, Thall PF, et al. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022;14(641):eabm6420. doi:10.1126/scitranslmed.abm6420
  27. Gounder MM, Rosenbaum E, Wu N, et al. A phase Ib/II randomized study of RO4929097, a gamma-secretase or notch inhibitor with or without vismodegib, a hedgehog inhibitor, in advanced sarcoma. Clin Cancer Res. 2022;28(8):1586-1594. doi:10.1158/1078-0432.CCR-21-3874
  28. Altieri DC. Wall Street doesn’t believe in this target. J Clin Oncol. 2022;40(16):1838-1840. doi:10.1200/JCO.22.00180
  29. Jacobson G, Fluss R, Dany-BenShushan A, et al. Coeliac plexus radiosurgery for pain management in patients with advanced cancer : study protocol for a phase II clinical trial. BMJ Open. 2022;12(3):e050169. doi:10.1136/bmjopen-2021-050169
  30. Dizman N, Meza L, Bergerot P, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2022;28(4):704-712. doi:10.1038/s41591-022-01694-6
  31. Sung AD, Giri VK, Tang H, et al. Home-based hematopoietic cell transplantation in the United States. Transplant Cell Ther. 2022;28(4):207.e1-207.e8. doi:10.1016/j.jtct.2022.01.01
  32. Mehdi Z, Petronek MS, Stolwijk JM, et al. Utilization of pharmacological ascorbate to enhance hydrogen peroxide-mediated radiosensitivity in cancer therapy. Int J Mol Sci. 2021;22(19):10880. doi:10.3390/ijms221910880
  33. Partridge AH, Niman SM, Ruggeri M, et al. Who are the women who enrolled in the POSITIVE trial: a global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast. 2021;59:327-338. doi:10.1016/j.breast.2021.07.021
  34. Petronek MS, Spitz DR, Allen BG. Iron-sulfur cluster biogenesis as a critical target in cancer. Antioxidants (Basel). 2021;10(9):1458. doi:10.3390/antiox10091458
  35. Wang VE, Blaser BW, Patel RK, et al. Inhibition of MET signaling with ficlatuzumab in combination with chemotherapy in refractory AML: clinical outcomes and high-dimensional analysis. Blood Cancer Discov. 2021;2(5):434-449. doi:10.1158/2643-3230.BCD-21-0055
  36. Weitzen R, Epstein N, Oberman B, Shevetz R, Hidvegi M, Berger R. Fermented wheat germ extract (FWGE) as a treatment additive for castration-resistant prostate cancer: a pilot clinical trial. Nutr Cancer. 2022;74(4):1338-1346. doi:10.1080/01635581.2021.1952457
  37. Rothschild SI, Zippelius A, Eboulet EI, et al; Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-a multicenter single-arm phase II trial. J Clin Oncol. 2021;39(26):2872-2880. doi:10.1200/JCO.21.00276
  38. Campbell RA, Li J, Malone L, Levy DA. Correlative analysis of vitamin D and omega-3 fatty acid intake in men on active surveillance for prostate cancer. Urology. 2021;155:110-116. doi:10.1016/j.urology.2021.04.050
  39. Du J, Carroll RS, Steers GJ, et al. Catalase modulates the radio-sensitization of pancreatic cancer cells by pharmacological ascorbate. Antioxidants (Basel). 2021;10(4):614. doi:10.3390/antiox10040614
  40. LoRusso PM, Sekulic A, Sosman JA, et al. Identifying treatment options for BRAFV600 wild-type metastatic melanoma: a SU2C/MRA genomics-enabled clinical trial. PLoS One. 2021;16(4):e0248097. doi:10.1371/journal.pone.0248097
  41. Caldwell KJ, Budhraja A, Opferman JT, Pui CH, Klco JM, Rubnitz JE. Activity of venetoclax against relapsed acute undifferentiated leukemia. Cancer. 2021;127(15):2608-2611. doi:10.1002/cncr.33531
  42. Seely D, Legacy M, Auer RC, et al. Adjuvant melatonin for the prevention of recurrence and mortality following lung cancer resection (AMPLCaRe): a randomized placebo controlled clinical trial. EClinicalMedicine. 2021;33:100763. doi:10.1016/j.eclinm.2021.100763
  43. Young PA, Márquez-Garbán DC, Noor ZS, et al. Investigation of combination treatment with an aromatase inhibitor exemestane and carboplatin-based therapy for postmenopausal women with advanced NSCLC. JTO Clin Res Rep. 2021;2(4):100150. doi:10.1016/j.jtocrr.2021.100150
  44. Petronek MS, Stolwijk JM, Murray SD, et al. Utilization of redox modulating small molecules that selectively act as pro-oxidants in cancer cells to open a therapeutic window for improving cancer therapy. Redox Biol. 2021;42:101864. doi:10.1016/j.redox.2021.101864
  45. Cushing CM, Petronek MS, Bodeker KL, et al. Magnetic resonance imaging (MRI) of pharmacological ascorbate-induced iron redox state as a biomarker in subjects undergoing radio-chemotherapy. Redox Biol. 2021;38:101804. doi:10.1016/j.redox.2020.101804
  46. Deng G. Acupuncture as a potential opioid-sparing pain management intervention for patients undergoing cancer treatment. Med Acupunct. 2020;32(6):394-395. doi:10.1089/acu.2020.1494
  47. Childs DS, Le-Rademacher JG, McMurray R, et al. Randomized trial of scrambler therapy for chemotherapy-induced peripheral neuropathy: crossover analysis. J Pain Symptom Manage. 2021;61(6):1247-1253. doi:10.1016/j.jpainsymman.2020.11.025
  48. Do KT, O’Sullivan Coyne G, Hays JL, et al. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2020;86(6):815-827. doi:10.1007/s00280-020-04176-z
  49. Sun Z, Niman SM, Pagani O, et al; POSITIVE Steering Committee. Estimation of historical control rate for a single arm de-escalation study – application to the POSITIVE trial. Breast. 2020;53:1-7. doi:10.1016/j.breast.2020.05.012
  50. Wong JYC, Filippi AR, Scorsetti M, Hui S, Muren LP, Mancosu P. Total marrow and total lymphoid irradiation in bone marrow transplantation for acute leukaemia. Lancet Oncol. 2020;21(10):e477-e487. doi:10.1016/S1470-2045(20)30342-9
  51. Weathers SP, Penas-Prado M, Pei BL, et al. Glioblastoma-mediated immune dysfunction limits CMV-specific T cells and therapeutic responses: results from a phase I/II trial. Clin Cancer Res. 2020;26(14):3565-3577. doi:10.1158/1078-0432.CCR-20-0176
  52. LaLonde L, Votruba K, Kentor R, Gatza E, Choi SW, Hoodin F. Cognitive complaints by hematopoietic cell transplantation recipients and change in neuropsychological performance over time. Support Care Cancer. 2021;29(1):247-254. doi:10.1007/s00520-020-05458-1
  53. Karol SE, Alexander TB, Budhraja A, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol. 2020;21(4):551-560. doi:10.1016/S1470-2045(20)30060-7
  54. Deng G, Giralt S, Chung DJ, et al. Reduction of opioid use by acupuncture in patients undergoing hematopoietic stem cell transplantation: secondary analysis of a randomized, sham-controlled trial. Pain Med. 2020;21(3):636-642. doi:10.1093/pm/pnz190
  55. Ramondetta LM, Hu W, Thaker PH, et al. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol. 2019;154(3):524-530. doi:10.1016/j.ygyno.2019.07.004
  56. Kariv R, Caspi M, Fliss-Isakov N, et al. Resorting the function of the colorectal cancer gatekeeper adenomatous polyposis coli. Int J Cancer. 2020;146(4):1064-1074. doi:10.1002/ijc.32557
  57. Loprinzi C, Le-Rademacher JG, Majithia N, et al. Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial. Support Care Cancer. 2020;28(3):1183-1197. doi:10.1007/s00520-019-04881-3
  58. Drusbosky LM, Singh NK, Hawkins KE, et al. A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients. Blood Adv. 2019;3(12):1837-1847. doi:10.1182/bloodadvances.2018028316
  59. Migliorini D, Dutoit V, Allard M, et al. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. Neuro Oncol. 2019;21(7):923-933. doi:10.1093/neuonc/noz040
  60. Boydell E, Marinari E, Migliorini D, Dietrich PY, Patrikidou A, Dutoit V. Exploratory study of the effect of IMA950/poly-ICLC vaccination on response to bevacizumab in relapsing high-grade glioma patients. Cancers (Basel). 2019;11(4):464. doi:10.3390/cancers11040464
  61. Drusbosky LM, Vidva R, Gera S, et al. Predicting response to BET inhibitors using computational modeling: a BEAT AML project study. Leuk Res. 2019;77:42-50. doi:10.1016/j.leukres.2018.11.010
  62. Hoodin F, LaLonde L, Errickson J, et al. Cognitive function and quality of life in vorinostat-treated patients after matched unrelated donor myeloablative conditioning hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25(2):343-353. doi:10.1016/j.bbmt.2018.09.015
  63. Kumar A, Drusbosky LM, Meacham A, et al. Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics. Leuk Res. 2019;78:3-11. doi:10.1016/j.leukres.2019.01.003
  64. Schoenfeld JD, Alexander MS, Waldron TJ, et al. Pharmacological ascorbate as a means of sensitizing cancer cells to radio-chemotherapy while protecting normal tissue. Semin Radiat Oncol. 2019;29(1):25-32. doi:10.1016/j.semradonc.2018.10.006
  65. Market M, Baxter KE, Angka L, Kennedy MA, Auer RC. The potential for cancer immunotherapy in targeting surgery-induced natural killer cell dysfunction. Cancers (Basel). 2018;11(1):2. doi:10.3390/cancers11010002
  66. Alexander MS, Wilkes JG, Schroeder SR, et al. Pharmacologic ascorbate reduces radiation-induced normal tissue toxicity and enhances tumor radiosensitization in pancreatic cancer. Cancer Res. 2018;78(24):6838-6851. doi:10.1158/0008-5472.CAN-18-1680
  67. Drexler B, Passweg JR, Tzankov A, et al; Swiss Group for Clinical Cancer Research (SAKK). The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. Haematologica. 2019;104(4):710-716. doi:10.3324/haematol.2018.200014
  68. Driessen C, Müller R, Novak U, et al. Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma. Blood. 2018;132(19):2097-2100. doi:10.1182/blood-2018-05-851170
  69. Wulfkuhle JD, Yau C, Wolf DM, et al. Evaluation of the HER/PI3K/AKT family signaling network as a predictive biomarker of pathologic complete response for patients with breast cancer treated with neratinib in the I-SPY 2 trial. JCO Precis Oncol. 2018;2:PO.18.00024. doi:10.1200/PO.18.00024
  70. Sun W, Triche T Jr, Malvar J, et al. A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium. Blood. 2018;131(10):1145-1148. doi:10.1182/blood-2017-09-803809
  71. Fox E, Levin K, Zhu Y, et al. Pantoprazole, an inhibitor of the organic cation transporter 2, does not ameliorate cisplatin-related ototoxicity or nephrotoxicity in children and adolescents with newly diagnosed osteosarcoma treated with methotrexate, doxorubicin, and cisplatin. Oncologist. 2018;23(7):762-e79. doi:10.1634/theoncologist.2018-0037
  72. Pidala J, Beato F, Kim J, et al. In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica. 2018;103(3):531-539. doi:10.3324/haematol.2017.171199
  73. Choi SW, Braun T, Henig I, et al. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. Blood. 2017;130(15):1760-1767. doi:10.1182/blood-2017-06-790469
  74. Deng G, Giralt S, Chung DJ, et al. Acupuncture for reduction of symptom burden in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial. Support Care Cancer. 2018;26(2):657-665. doi:10.1007/s00520-017-3881-7
  75. Aiken R, Axelson M, Harmenberg J, Klockare M, Larsson O, Wassberg C. Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response. Oncotarget. 2017;8(46):81501-81510. doi:10.18632/oncotarget.20662
  76. Beg MS, Huang X, Silvers MA, et al. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. J Surg Oncol. 2017;116(1):83-88. doi:10.1002/jso.24624
  77. Salazar LG, Lu H, Reichow JL, et al. Topical imiquimod plus nab-paclitaxel for breast cancer cutaneous metastases: a phase 2 clinical trial. JAMA Oncol. 2017;3(7):969-973. doi:10.1001/jamaoncol.2016.6007
  78. Stein A, Palmer J, Tsai NC, et al. Phase I trial of total marrow and lymphoid irradiation transplantation conditioning in patients with relapsed/refractory acute leukemia. Biol Blood Marrow Transplant. 2017;23(4):618-624. doi:10.1016/j.bbmt.2017.01.067
  79. Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561-2569. doi:10.1056/NEJMoa1610497
  80. Aycinena AC, Valdovinos C, Crew KD, et al. Barriers to recruitment and adherence in a randomized controlled diet and exercise weight loss intervention among minority breast cancer survivors. J Immigr Minor Health. 2017;19(1):120-129. doi:10.1007/s10903-015-0310-1
  81. Caspi M, Firsow A, Rajkumar R, et al. A flow cytometry-based reporter assay identifies macrolide antibiotics as nonsense mutation read-through agents. J Mol Med (Berl). 2016;94(4):469-482. doi:10.1007/s00109-015-1364-1
  82. Li L, Goedegebuure SP, Fleming TP, Gillanders WE. Developing a clinical development paradigm for translation of a mammaglobin-A DNA vaccine. Immunotherapy. 2015;7(7):709-711. doi:10.2217/imt.15.40
  83. Holcombe RF, Martinez M, Planutis K, Planutiene M. Effects of a grape-supplemented diet on proliferation and Wnt signaling in the colonic mucosa are greatest for those over age 50 and with high arginine consumption. Nutr J. 2015;14:62. doi:10.1186/s12937-015-0050-z
  84. Frankel AE, Woo JH, Ahn C, et al. Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica. 2015;100(6):794-800. doi:10.3324/haematol.2015.123711
  85. Zent CS, Call TG, Bowen DA, et al. Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. Leuk Lymphoma. 2015;56(8):2373-2378. doi:10.3109/10428194.2015.1016932
  86. Delgado-Cruzata L, Zhang W, McDonald JA, et al. Dietary modifications, weight loss, and changes in metabolic markers affect global DNA methylation in Hispanic, African American, and Afro-Caribbean breast cancer survivors. J Nutr. 2015;145(4):783-790. doi:10.3945/jn.114.202853
  87. Wesa KM, Segal NH, Cronin AM, et al. Serum 25-hydroxy vitamin D and survival in advanced colorectal cancer: a retrospective analysis. Nutr Cancer. 2015;67(3):424-430. doi:10.1080/01635581.2015.998838
  88. Tiriveedhi V, Tucker N, Herndon J, et al. Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer. Clin Cancer Res. 2014;20(23):5964-5975. doi:10.1158/1078-0432.CCR-14-0059
  89. Chen G, Gupta R, Petrik S, et al. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res. 2014;2(10):949-961. doi:10.1158/2326-6066.CIR-14-0058
  90. Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014;6(222):222ra18. doi:10.1126/scitranslmed.3007154
  91. Disis ML, Dang Y, Coveler AL, et al. HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers. Cancer Immunol Immunother. 2014;63(2):101-109. doi:10.1007/s00262-013-1489-4
  92. Cutler C, Kim HT, Bindra B, et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013;122(8):1510-1517. doi:10.1182/blood-2013-04-495895
  93. Stephenson CM, Levin RD, Spector T, Lis CG. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;72(1):139-146. doi:10.1007/s00280-013-2179-9
  94. Greenlee HA, Crew KD, Mata JM, et al. A pilot randomized controlled trial of a commercial diet and exercise weight loss program in minority breast cancer survivors. Obesity (Silver Spring). 2013;21(1):65-76. doi:10.1002/oby.20245
  95. Nikiforow S, Kim HT, Bindra B, et al. Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(5):804-811. doi:10.1016/j.bbmt.2013.02.009
  96. Hollis BW, Marshall DT, Savage SJ, Garrett-Mayer E, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation, low-risk prostate cancer, and health disparities. J Steroid Biochem Mol Biol. 2013;136:233-237. doi:10.1016/j.jsbmb.2012.11.012
  97. Mahadevan D, Chiorean EG, Harris WB, et al. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer. 2012;48(18):3319-3327. doi:10.1016/j.ejca.2012.06.027
  98. Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, et al. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs. 2013;31(3):707-713. doi:10.1007/s10637-012-9866-y
  99. Foglietta M, Neelapu SS, Kwak LW, et al. Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients. Bone Marrow Transplant. 2013;48(2):269-277. doi:10.1038/bmt.2012.132
  100. Garrett-Mayer E, Wagner CL, Hollis BW, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation (4000 IU/d for 1 y) eliminates differences in circulating 25-hydroxyvitamin D between African American and white men. Am J Clin Nutr. 2012;96(2):332-336. doi:10.3945/ajcn.112.034256
  101. Marshall DT, Savage SJ, Garrett-Mayer E, et al. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012;97(7):2315-2324. doi:10.1210/jc.2012-1451
  102. Torkelson CJ, Sweet E, Martzen MR, et al. Phase 1 clinical trial of Trametes versicolor in women with breast cancer. ISRN Oncol. 2012;2012:251632. doi:10.5402/2012/251632
  103. Laport GG, Sheehan K, Baker J, et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(11):1679-1687. doi:10.1016/j.bbmt.2011.05.012
  104. Finkelstein SE, Iclozan C, Bui MM, et al. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys. 2012;82(2):924-932. doi:10.1016/j.ijrobp.2010.12.068
  105. Formelli F, Cavadini E, Luksch R, Garaventa A, Appierto V, Persiani S. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients. Cancer Chemother Pharmacol. 2010;66(5):993-998. doi:10.1007/s00280-010-1370-5
  106. Standish LJ, Sweet ES, Novack J, et al. Breast cancer and the immune system. J Soc Integr Oncol. 2008;6(4):158-168. https://pubmed.ncbi.nlm.nih.gov/19134448/
  107. Standish LJ, Torkelson C, Hamill FA, et al. Immune defects in breast cancer patients after radiotherapy. J Soc Integr Oncol. 2008;6(3):110-121. https://pubmed.ncbi.nlm.nih.gov/19087768/
  108. Standish LJ, Wenner CA, Sweet ES, et al. Trametes versicolor mushroom immune therapy in breast cancer. J Soc Integr Oncol. 2008;6(3):122-128. https://pubmed.ncbi.nlm.nih.gov/19087769/
  109. Nagula S, Ishill N, Nash C, et al. Quality of life and symptom control after stent placement or surgical palliation of malignant colorectal obstruction. J Am Coll Surg. 2010;210(1):45-53. doi:10.1016/j.jamcollsurg.2009.09.039
  110. Hrushesky WJM, Grutsch J, Wood P, et al. Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms. Integr Cancer Ther. 2009;8(4):387-397. doi:10.1177/1534735409352086
  111. Disis ML, Wallace DR, Gooley TA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009;27(28):4685-4692. doi:10.1200/JCO.2008.20.6789
  112. Protiva P, Cross HS, Hopkins ME, et al. Chemoprevention of colorectal neoplasia by estrogen: potential role of vitamin D activity. Cancer Prev Res (Phila). 2009;2(1):43-51. doi:10.1158/1940-6207.CAPR-08-0103
  113. Krishnan AP, Asher IM, Davis D, Okunieff P, O’Dell WG. Evidence that MR diffusion tensor imaging (tractography) predicts the natural history of regional progression in patients irradiated conformally for primary brain tumors. Int J Radiat Oncol Biol Phys. 2008;71(5):1553-1562. doi:10.1016/j.ijrobp.2008.04.017
  114. Rao RD, Flynn PJ, Sloan JA, et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer. 2008;112(12):2802-2808. doi:10.1002/cncr.23482
  115. Formelli F, Cavadini E, Luksch R, et al. Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide. Cancer Chemother Pharmacol. 2008;62(4):655-665. doi:10.1007/s00280-007-0649-7
  116. Rao RD, Michalak JC, Sloan JA, et al; North Central Cancer Treatment Group. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110(9):2110-2118. doi: 10.1002/cncr.23008
  117. Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer. 2007;57(3):365-372. doi:10.1016/j.lungcan.2007.04.002
  118. Malbaša T, Kodish E, Santacroce SJ. Adolescent adherence to oral therapy for leukemia: a focus group study. J Pediatr Oncol Nurs. 2007;24(3):139-151. doi:10.1177/1043454206298695
  119. Cohen LA, Crespin JS, Wolper C, et al. Soy isoflavone intake and estrogen excretion patterns in young women: effect of probiotic administration. In Vivo. 2007;21(3):507-512. https://pubmed.ncbi.nlm.nih.gov/17591361/
  120. Or R, Hadar E, Bitan M, et al. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(12):1295-1301. doi:10.1016/j.bbmt.2006.07.014
  121. Lin Y, Goedegebuure PS, Tan MC, et al. Proteins associated with disease and clinical course in pancreas cancer: a proteomic analysis of plasma in surgical patients. J Proteome Res. 2006;5(9):2169-2176. doi:10.1021/pr0600374
  122. Hirshfeld E, Weiss L, Kasir J, Zeira M, Slavin S, Shapira MY. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation? Bone Marrow Transplant. 2006;38(5):359-364. doi:10.1038/sj.bmt.1705449
  123. Tiersten A, Selleck M, Smith DH, et al. Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer. Int J Gynecol Cancer. 2006;16(1):57-64. doi:10.1111/j.1525-1438.2006.00278.x
  124. Traore F, O’Riordan MA, Myers C, et al. How low is too low? Use of cluster analysis to define low levels of mercaptopurine metabolites. Pediatr Blood Cancer. 2006;46(2):187-192. doi:10.1002/pbc.20518
  125. Levin RD, Daehler MA, Grutsch JF, et al. Circadian function in patients with advanced non-small-cell lung cancer. Br J Cancer. 2005;93(11):1202-1208. doi:10.1038/sj.bjc.6602859
  126. Yang I, Weiss L, Abdul-Hai A, Kasir J, Reich S, Slavin S. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease. Cancer Res. 2005;65(21):9735-9740. doi:10.1158/0008-5472.CAN-04-4175
  127. Shapira MY, Resnick IB, Bitan M, et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant. 2005;36(12):1097-1101. doi:10.1038/sj.bmt.1705185
  128. Dadabayev AR, Wang Z, Zhang Y, Zhang J, Robinson WR, Lim SH. Cancer immunotherapy targeting Sp17: when should the laboratory findings be translated to the clinics? Am J Hematol. 2005;80(1):6-11. doi:10.1002/ajh.20415
  129. Bitan M, Or R, Shapira MY, et al. Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent. Haematologica. 2005;90(8):1089-1095. https://pubmed.ncbi.nlm.nih.gov/16079108/
  130. Bitan M, Shapira MY, Resnick IB, et al. Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133+-purified stem cells. Exp Hematol. 2005;33(6):713-718. doi:10.1016/j.exphem.2005.03.004
  131. Yannelli JR, Sturgill J, Foody T, Hirschowitz E. The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC). Lung Cancer. 2005;47(3):337-350. doi:10.1016/j.lungcan.2004.08.008
  132. Hesselbrock DR, Kurpios N, Hassell JA, Watson MA, Fleming TP. PEA3, AP-1, and a unique repetitive sequence all are involved in transcriptional regulation of the breast cancer-associated gene, mammaglobin. Breast Cancer Res Treat. 2005;89(3):289-296. doi:10.1007/s10549-004-2622-z
  133. Disis ML, Salazar LG, Knutson KL. Peptide-based vaccines in breast cancer. Breast Dis. 2004;20:3-11. doi:10.3233/bd-2004-20102
  134. Artz AS, Van Besien K, Zimmerman T, et al. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: the University of Chicago experience. Bone Marrow Transplant. 2005;35(3):253-260. doi:10.1038/sj.bmt.1704760
  135. Shapira MY, Hirshfeld E, Weiss L, et al. Mycophenolate mofetil does not suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model. Cancer Immunol Immunother. 2005;54(4):383-388. doi:10.1007/s00262-004-0614-9
  136. Wang Z, Zhang Y, Ramsahoye B, Bowen D, Lim SH. Sp17 gene expression in myeloma cells is regulated by promoter methylation. Br J Cancer. 2004;91(8):1597-1603. doi:10.1038/sj.bjc.6602160
  137. Goedegebuure PS, Watson MA, Viehl CT, Fleming TP. Mammaglobin-based strategies for treatment of breast cancer. Curr Cancer Drug Targets. 2004;4(6):531-542. doi:10.2174/1568009043332862
  138. Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol. 2004;24(5):571-578. doi:10.1023/B:JOCI.0000040928.67495.52
  139. Panigrahi S, Morecki S, Yacovlev E, Gelfand Y, Kassir J, Slavin S. A novel approach for prevention of lethal GVHD by selective elimination of alloreactive donor lymphocytes prior to stem cell transplantation. Exp Hematol. 2004;32(8):756-764. doi:10.1016/j.exphem.2004.04.009
  140. Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol. 2004;22(14):2808-2815. doi:10.1200/JCO.2004.01.074
  141. Morecki S, Panigrahi S, Pizov G, et al. Effect of KRN7000 on induced graft-vs-host disease. Exp Hematol. 2004;32(7):630-637. doi:10.1016/j.exphem.2004.04.005
  142. Shapira MY, Resnick IB, Bitan M, et al. Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients. Bone Marrow Transplant. 2004;34(2):155-159. doi:10.1038/sj.bmt.1704540
  143. Elkin G, Prigozhina TB, Slavin S. Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol. 2004;32(6):579-584. doi:10.1016/j.exphem.2004.03.007
  144. Disis ML, Schiffman K, Guthrie K, et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein–based vaccine. J Clin Oncol. 2004;22(10):1916-1925. doi:10.1200/JCO.2004.09.005
  145. Weiss L, Reich S, Mandelboim O, Slavin S. Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy. Bone Marrow Transplant. 2004;33(11):1137-1141. doi:10.1038/sj.bmt.1704475
  146. Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Junghans RP. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate. 2004;61(1):12-25. doi:10.1002/pros.20073
  147. Slavin S, Morecki S, Weiss L, Shapira MY, Resnick I, Or R. Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy—from bench to patient bedside. Semin Oncol. 2004;31(1):4-21. doi:10.1053/j.seminoncol.2003.10.016
  148. Harlin H, Artz AS, Mahowald M, et al. Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells. Bone Marrow Transplant. 2004;33(5):491-497. doi:10.1038/sj.bmt.1704385
  149. Morecki S, Yacovlev E, Gelfand Y, Vilensky A, Slavin S. Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect. Biol Blood Marrow Transplant. 2004;10(1):40-48. doi:10.1016/j.bbmt.2003.09.013
  150. Weiss L, Or R, Slavin S, Naparstek E, Reich S, Abdul-Hai A. Immunotherapy of murine leukemia following non-myeloablative conditioning with naïve or G-CSF mobilized blood or bone marrow stem cells. Cancer Immunol Immunother. 2004;53(4):358-362. doi:10.1007/s00262-003-0440-5
  151. Ji YH, Weiss L, Zeira M, et al. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses. Bone Marrow Transplant. 2003;32(5):495-504. doi:10.1038/sj.bmt.1704150
  152. Disis ML, Rivkin S. Future directions in the management of ovarian cancer. Hematol Oncol Clin North Am. 2003;17(4):1075-1085. doi:10.1016/s0889-8588(03)00054-6
  153. Garaventa A, Luksch R, Lo Piccolo MS, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res. 2003;9(6):2032-2039. https://pubmed.ncbi.nlm.nih.gov/12796365/
  154. Slavin S, Morecki S, Weiss L, Or R. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Crit Rev Oncol Hematol. 2003;46(2):139-163. doi:10.1016/s1040-8428(02)00108-7
  155. Or R, Shapira MY, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood. 2003;101(2):441-445. doi:10.1182/blood-2002-02-0535
  156. Prigozhina TB, Gurevitch O, Elkin G, Morecki S, Yakovlev E, Slavin S. CD40 ligand-specific antibodies synergize with cyclophosphamide to promote long-term transplantation tolerance across MHC barriers but inhibit graft-vs-leukemia effects of transplanted cells. Exp Hematol. 2003;31(1):81-88. doi:10.1016/s0301-472x(02)01009-3
  157. El-Bayoumy K, Richie JP Jr, Boyiri T, et al. Influence of selenium-enriched yeast supplementation on biomarkers of oxidative damage and hormone status in healthy adult males: a clinical pilot study. Cancer Epidemiol Biomarkers Prev. 2002;11(11):1459-1465. https://pubmed.ncbi.nlm.nih.gov/12433727/
  158. Slavin S, Aker M, Shapira MY, Panigrahi S, Gabriel C, Or R. Non-myeloablative stem cell transplantation for the treatment of cancer and life-threatening non-malignant disorders; past accomplishments and future goals. Transfus Apher Sci. 2002;27(2):159-166. doi:10.1016/s1473-0502(02)00038-1
  159. Chiriva-Internati M, Wang Z, Salati E, Bumm K, Barlogie B, Lim SH. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood. 2002; 100(3):961-965. doi:10.1182/blood-2002-02-0408
  160. Bashey A, Cantwell MJ, Kipps TJ. Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells. Br J Haematol. 2002;118(2):506-513. doi:10.1046/j.1365-2141.2002.03603.x
  161. Schiffman K, Rinn K, Disis ML. Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients. Breast Cancer Res Treat. 2002;74(1):17-23. doi:10.1023/a:1016009317796
  162. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 2002;20(11):2624-2632. doi:10.1200/JCO.2002.06.171
  163. Disis ML, Rinn K, Knutson KL, et al. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood. 2002;99(8):2845-2850. doi:10.1182/blood.v99.8.2845
  164. Slavin S, Morecki S, Weiss L, Or R. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. J Hematother Stem Cell Res. 2002;11(2):265-276. doi:10.1089/152581602753658457
  165. Slavin S, Nagler A, Shapira MY, Aker M, Gabriel C, Or R. Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation. J Clin Immunol. 2002;22(2):64-69. doi:10.1023/a:1014423617596
  166. Bernhard H, Salazar L, Schiffman K, et al. Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer. 2002;9(1):33-44. doi:10.1677/erc.0.0090033
  167. Prigozhina TB, Gurevitch O, Morecki S, Yakovlev E, Elkin G, Slavin S. Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models. Exp Hematol. 2002;30(1):89-96. doi:10.1016/s0301-472x(01)00759-7
  168. Slavin S. Maternal-fetal relationship, natural chimerism and bilateral transplantation tolerance as the basis for non-myeloablative stem cell transplantation. Int J Hematol. 2002;76(Suppl 1):172-175. doi:10.1007/BF03165240
  169. Knutson KL, Bishop MR, Schiffman K, Disis ML. Immunotherapy for breast cancer. Cancer Chemother Biol Response Modif. 2002;20:351-369. https://pubmed.ncbi.nlm.nih.gov/12703214/
  170. Slavin S, Nagler A, Aker M, Shapira MY, Cividalli G, Or R. Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders. Rev Clin Exp Hematol. 2001;5(2):135-146. doi:10.1046/j.1468-0734.2001.00036.x
  171. Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis. 2001;3(2):79-87. doi:10.1034/j.1399-3062.2001.003002079.x
  172. Disis ML, Schiffman K. Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol. 2001;28(6 Suppl 18):12-20. https://pubmed.ncbi.nlm.nih.gov/11774201/
  173. Morecki S, Gelfand Y, Nagler A, et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant. 2001;28(3):243-249. doi:10.1038/sj.bmt.1703118
  174. Hemminki A, Belousova N, Zinn KR, et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther. 2001;4(3):223-231. doi:10.1006/mthe.2001.0446
  175. Patel PS, Raval GN, Patel DD, et al. A study of various sociodemographic factors and plasma vitamin levels in oral and pharyngeal cancer in Gujarat, India. Asian Pac J Cancer Prev. 2001;2(3):215-224. https://pubmed.ncbi.nlm.nih.gov/12718634/
  176. Slavin S, Or R, Aker M, et al. Nonmyeloablative stem cell transplantation for the treatment of cancer and life-threatening nonmalignant disorders: past accomplishments and future goals. Cancer Chemother Pharmacol. 2001;48(Suppl 1):S79-S84. doi:10.1007/s002800100311
  177. Slavin S, Nagler A, Shapira M, Panigrahi S, Samuel S, Or A. Non-myeloablative allogeneic stem cell transplantation focusing on immunotherapy of life-threatening malignant and non-malignant diseases. Crit Rev Oncol Hematol. 2001;39(1-2):25-29. doi:10.1016/s1040-8428(01)00121-4
  178. Rose C, Green M, Webber S, Ellis D, Reyes J, Rowe D. Pediatric solid-organ transplant recipients carry chronic loads of Epstein-Barr virus exclusively in the immunoglobulin D-negative B-cell compartment. J Clin Microbiol. 2001;39(4):1407-1415. doi:10.1128/JCM.39.4.1407-1415.2001
  179. Knutson KL, Disis ML. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine. Clin Breast Cancer. 2001;2(1):73-79. doi:10.3816/CBC.2001.n.014
  180. Newton DA, Acierno PM, Metts MC, Baron PL, Brescia FJ, Gattoni-Celli S. Semiallogeneic cancer vaccines formulated with granulocyte-macrophage colony-stimulating factor for patients with metastatic gastrointestinal adenocarcinomas: a pilot phase I study. J Immunother. 2001;24(1):19-26. doi:10.1097/00002371-200101000-00003
  181. Meters D, Storkus W, Zeevi A, et al. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals. Transplantation. 2000;70(10):1507-1515. doi:10.1097/00007890-200011270-00019
  182. Alvarez RD, Gomez-Navarro J, Wang M, et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther. 2000;2(5):524-530. doi:10.1006/mthe.2000.0194
  183. Kelly FJ, Miller CR, Buchsbaum DJ, et al. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro. Clin Cancer Res. 2000;6(11):4323-4333. https://pubmed.ncbi.nlm.nih.gov/11106250/
  184. Qu L, Green M, Webber S, Reyes J, Ellis D, Rowe D. Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads. J Infect Dis. 2000;182(4):1013-1021. doi:10.1086/315828
  185. Nagler A, Or R, Naparstek E, Varadi G, Slavin S. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Exp Hematol. 2000;28(9):1096-1104. doi:10.1016/s0301-472x(00)00511-7
  186. Green M, Bueno J, Rowe D, et al. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation. 2000;70(4):593-596. doi:10.1097/00007890-200008270-00010
  187. Alvarez RD, Barnes MN, Gomez-Navarro J, et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res. 2000;6(8):3081-3087. https://pubmed.ncbi.nlm.nih.gov/10955787/
  188. Skubitz KM, Anderson PM. Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial. Anticancer Drugs. 2000;11(7):555-563. doi:10.1097/00001813-200008000-00006
  189. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat. 2000;62(3):245-252. doi:10.1023/a:1006438507898
  190. Schiffman K, Disis ML. HER2/neu peptide-based vaccines, with GM-CSF as an adjuvant, in patients with advanced-stage HER2/neu-expressing cancers. Clin Lung Cancer. 2000;2(1):74-77. doi:10.3816/clc.2000.n.021
  191. Disis ML, West HL, Schiffman K. Cancer vaccines for the treatment and prevention of non small-cell lung cancer. Clin Lung Cancer. 2000;1(4):294-301. doi:10.3816/clc.2000.n.012
  192. Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res. 2000;6(4):1347-1350. https://pubmed.ncbi.nlm.nih.gov/10778962/
  193. Messmann RA, Vitetta ES, Headlee D, et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res. 2000;6(4):1302-1313. https://pubmed.ncbi.nlm.nih.gov/10778955/
  194. Newton DA, Romano C, Gattoni-Celli S. Semiallogeneic cell hybrids as therapeutic vaccines for cancer. J Immunother. 2000;23(2):246-254. doi:10.1097/00002371-200003000-00009
  195. Nair SK, Hull S, Coleman D, Gilboa E, Lyerly HK, Morse MA. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer. 1999;82(1):121-124. doi:10.1002/(sici)1097-0215(19990702)82:1<121::aid-ijc20>3.0.co;2-x
  196. Knutson KL, Schiffman K, Rinn K, Disis ML. Immunotherapeutic approaches for the treatment of breast cancer. J Mammary Gland Biol Neoplasia. 1999;4(4):353-365. doi:10.1023/a:1018714300217
  197. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res. 1999;5(6):1289-1297. https://pubmed.ncbi.nlm.nih.gov/10389911/
  198. Disis ML, McNeel DG, Rinn K, Schiffman KA, Knutson KL. Peptide-based tumor vaccines. Curr Opin Oncol Endocrinol Metab Investig Drugs. 1999;1(3):253-259.
  199. Kirkwood JM, Farkas DL, Chakraborty A, et al. Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med. 1999;5(1):11-20. https://pubmed.ncbi.nlm.nih.gov/10072444/
  200. Smith MR, Xie T, Joshi I, Schilder RJ. Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells. Br J Haematol. 1998;102(4):1090-1097. doi:10.1046/j.1365-2141.1998.00850.x
  201. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756-763. https://pubmed.ncbi.nlm.nih.gov/9446633/
  202. Disis ML, Cheever MA. HER-2/neu oncogenic protein: issues in vaccine development. Crit Rev Immunol. 1998;18(1-2):37-45. doi:10.1615/critrevimmunol.v18.i1-2.50
  203. Nalesnik MA, Rao AS, Furukawa H, et al. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation. 1997;63(9):1200-1205. doi:10.1097/00007890-199705150-00002
  204.  

20 North Martingale Road
Suite 180
Schaumburg, IL 60173
888-221-CURE

© 2024 Gateway for Cancer ResearchSM

DONATE NOW

APPLY FOR A GRANT

EXPLORE CLINICAL TRIALS

CONTACT US

PRIVACY POLICY

GuideStar Platinum Seal of Transparency 2020

Stay Connected with Gateway

Get the latest news from our funded trials, trusted tips for healthy living and ways to support our critical work.